Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | KCNB1 | Q14721 | 5/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864005 | 0.86 | ADRB2 (0.43) | PTGDR2TRPM4ADRB2SMPD3KCNB1 | |
| SCHEMBL3712377 | 0.85 | TRPM4 (0.48) | PTGDR2TRPM4ADRB2HDAC2LOXL2 | |
| SCHEMBL7907897 | 0.84 | MAPK14 (0.45) | PTGDR2TRPM4ADRB2SMPD3KCNB1 | |
| SCHEMBL3352615 | 0.76 | KDM4E (0.53) | ADRB2SMPD3HDAC2LOXL2ABL1 | |
| SCHEMBL2276490 | 0.75 | HDAC2 (0.69) | TRPM4HDAC2KMT2AMAPK14SMO | |
| SCHEMBL1307119 | 0.74 | TUBB4A (0.55) | SMPD3KMT2ALMNASMN1; SMN2 | |
| SCHEMBL3741524 | 0.74 | KAT6A (0.55) | PTGDR2SMPD3HDAC2ABL1BCR | |
| SCHEMBL8213638 | 0.72 | GAA (0.50) | SMPD3ABL1LMNASMN1; SMN2 | |
| SCHEMBL8240124 | 0.71 | LOXL2 (0.67) | ADRB2SMPD3LOXL2ABL1BCR | |
| SCHEMBL408167 | 0.71 | SMPD3 (0.46) | ADRB2SMPD3HDAC2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PTGDR2 3851/4885TRPM4 4109/4885ADRB2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.